Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling

被引:115
作者
Nickel, Nils P. [1 ]
Spiekerkoetter, Edda [2 ,3 ]
Gu, Mingxia [1 ]
Li, Caiyun G. [1 ]
Li, Hai [1 ]
Kaschwich, Mark [1 ]
Diebold, Isabel [1 ]
Hennigs, Jan K. [1 ]
Kim, Ki-Yoon [1 ]
Miyagawa, Kazuya [1 ]
Wang, Lingli [1 ]
Cao, Aiqin [1 ]
Sa, Silin [1 ]
Jiang, Xinguo [2 ,3 ]
Stockstill, Raymond W. [1 ]
Nicolls, Mark R. [2 ,3 ]
Zamanian, Roham T. [2 ,3 ]
Bland, Richard D. [1 ]
Rabinovitch, Marlene [1 ]
机构
[1] Stanford Univ, Sch Med, Vera Moulton Wall Ctr Pulm Vasc Dis, Dept Pediat, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Vera Moulton Wall Ctr Pulm Vasc Dis, Dept Med, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Cardiovasc Inst, Stanford, CA 94305 USA
关键词
neutrophil elastase inhibition; apelin; arterial smooth muscle cells; endothelial cell apoptosis; pulmonary vascular regeneration and angiogenesis; SERINE ELASTASE INHIBITOR; SMOOTH-MUSCLE-CELLS; TENASCIN-C; EXPRESSION; PATHOGENESIS; SURVIVAL; MICE; OVEREXPRESSION; MONOCROTALINE; DYSFUNCTION;
D O I
10.1164/rccm.201412-2291OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Pulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity. Synthetic elastase inhibitors reverse experimental pulmonary hypertension but cause hepatotoxicity in clinical studies. The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe experimental pulmonary hypertension or vascular pathology in the human disease was unknown. Objectives: To assess elafin-mediated regression of pulmonary vascular pathology in rats and in lung explants from patients with pulmonary hypertension. To determine if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism. Methods: Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease. Pulmonary arterial endothelial cells from patients and control subjects were used to determine the efficacy and mechanism of elafin-mediated BMPR2 signaling. Measurements and Main Results: In Sugen/hypoxia rats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes. Elafin improved endothelial function by increasing apelin, a BMPR2 target. Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture. In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling. This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1. Conclusions: Elafin reverses ubliterative changes in pulmonary arteries via elastase inhibition and caveolin- 1 dependent amplification of BMPR2 signaling.
引用
收藏
页码:1273 / 1286
页数:14
相关论文
共 51 条
[41]   Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling [J].
Taraseviciene-Stewart, Laimute ;
Nicolls, Mark R. ;
Kraskauskas, Donatas ;
Scerbavicius, Robertas ;
Burns, Nana ;
Cool, Carlyne ;
Wood, Kathy ;
Parr, Jane E. ;
Boackle, Susan A. ;
Voelkel, Norbert F. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (12) :1280-1289
[42]   Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival - Implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension [J].
Teichert-Kuliszewska, K ;
Kutryk, MJB ;
Kuliszewski, MA ;
Karoubi, G ;
Courtman, DW ;
Zucco, L ;
Granton, J ;
Stewart, DJ .
CIRCULATION RESEARCH, 2006, 98 (02) :209-217
[43]  
Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO
[44]  
2-K
[45]   Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats [J].
Toba, Michie ;
Alzoubi, Abdallah ;
O'Neill, Kealan D. ;
Gairhe, Salina ;
Matsumoto, Yuri ;
Oshima, Kaori ;
Abe, Kohtaro ;
Oka, Masahiko ;
McMurtry, Ivan F. .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2014, 306 (02) :H243-H250
[46]  
TODOROVICHHUNTER L, 1988, LAB INVEST, V58, P184
[47]   Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells [J].
Valdimarsdottir, G ;
Goumans, MJ ;
Rosendahl, A ;
Brugman, M ;
Itoh, S ;
Lebrin, F ;
Sideras, P ;
ten Dijke, P .
CIRCULATION, 2002, 106 (17) :2263-2270
[48]   Caveolin-1 regulates BMPRII localization and signaling in vascular smooth muscle cells [J].
Wertz, Jeffrey W. ;
Bauer, Philip M. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 375 (04) :557-561
[49]   ELAFIN IS A POTENT INHIBITOR OF PROTEINASE-3 [J].
WIEDOW, O ;
LUDEMANN, J ;
UTECHT, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 174 (01) :6-10
[50]   Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis [J].
Zaidi, SHE ;
Hui, CC ;
Cheah, AYL ;
You, XM ;
Husain, M ;
Rabinovitch, M .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (08) :1211-1219